NT-proBNP point-of-care testing for predicting mortality in end-stage renal disease: A survival analysis.
ESRD
End-stage renal disease
N-Terminal-pro brain natriuretic peptide
NT-Pro BNP
Survival analysis
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
received:
21
12
2023
revised:
29
04
2024
accepted:
29
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
This study examines the predictive value of elevated N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels for mortality among patients with end-stage renal disease (ESRD). Data from 768 ESRD patients, excluding those with cancer or lost follow-up, were analyzed using Kaplan-Meier curves and Cox proportional hazards models over three years. Results indicated that patients with very high NT-pro BNP levels had shorter average survival times and a significantly higher risk of mortality (hazard ratio 1.43). Advanced age, ICU admission, and comorbidities like cerebrovascular diseases and chronic obstructive pulmonary disease also contributed to increased mortality risks. Thus, elevated NT-pro BNP is an independent risk factor for mortality in ESRD patients.
Identifiants
pubmed: 38742053
doi: 10.1016/j.heliyon.2024.e30581
pii: S2405-8440(24)06612-X
pmc: PMC11089362
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e30581Informations de copyright
© 2024 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.